Screener
Recursion Pharmaceuticals, Inc. RXRX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities | ||
| Accounts payable | $12,672 | $18,118 |
| Accrued expenses and other liabilities | 56,936 | 70,230 |
| Unearned revenue | 27,586 | 37,605 |
| Operating lease liabilities | 13,249 | 12,663 |
| Notes payable and financing lease liabilities | 9,443 | 9,091 |
| Total current liabilities | 119,886 | 147,707 |
| Unearned revenue, non-current | 112,818 | 114,012 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s deferred revenue?
- Recursion Pharmaceuticals, Inc. (RXRX) reported deferred revenue of $27.59M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s deferred revenue changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s deferred revenue decreased by 30.5% year-over-year, from $39.69M to $27.59M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s deferred revenue?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s deferred revenue has grown at a 30.3% compound annual growth rate (CAGR), from $10M to $37.61M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Recursion Pharmaceuticals, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude